EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes
Viruses · 2024
DOI: 10.3390/v16081294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Nancy Law und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Virus Activation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The acquisition or reactivation of Epstein–Barr virus (EBV) after allogeneic Hematopoietic Stem Cell Transplant (HSCT) can be associated with complications including the development of post-transplant lymphoproliferative disorder (PTLD), which is associated with significant morbidity and mortality. A number of risk factors for PTLD have been defined, including T-cell depletion, and approaches to monitoring EBV, especially in high-risk patients, with the use of preemptive therapy upon viral activation have been described. Newer therapies for the preemption or treatment of PTLD, such as EBV-specific cytotoxic T-cells, hold promise. Further studies to help define risks, diagnosis, and treatment of EBV-related complications are needed in this at-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA.
- Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA 91010, USA.
ORCID-Profile: Nancy Law, Cathy Logan, Randy Taplitz
Zitieren
APA
Law, N., Logan, C., & Taplitz, R. (2024). EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes. Viruses. https://doi.org/10.3390/v16081294
Vancouver
Law N, Logan C, Taplitz R. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes. Viruses. 2024. doi:10.3390/v16081294
BibTeX
@article{Law2024,
author = {Law, Nancy and Logan, Cathy and Taplitz, Randy},
title = {EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081294}
}
EUVIMED